Table 5.
Vaccination in special populations of inflammatory bowel disease patients
| Pregnancy | ||
| Category B | Category C | Category X |
| Influenza (LAIV) | PPSV 23 | Varicella, if non-immune |
| 1 dose upon completion or termination of pregnancy and before discharge from health care facility. | ||
| 2nd dose 4-8 wk later. | ||
| Influenza (IIV) | Zoster | |
| Boostrix (Tdap) | Adacel (Tdap) | |
| 1 dose of Tdap vaccine during each pregnancy regardless of immunization status | 1 dose of Tdap vaccine during each pregnancy regardless of immunization status | |
| HPV 4, HPV 2 | Meningococcus | |
| PCV 13 | Hepatitis A and B vaccine | |
| MMR, if non-immune | ||
| 1 dose upon completion or termination of pregnancy and before discharge from health care facility. | ||
| 2nd dose 4-8 wk later. | ||
| The IBD traveler | ||
| Vaccine | Type | Travel related indication |
| Yellow fever | Live | Parts of South America and sub-Saharan Africa |
| Typhoid | Live and Inactivated | Asia, Africa, Central and South America, The Caribbean, Oceania |
| Polio | Live | |
| Influenza | Inactivated | |
| BCG vaccine | Live | Travel to highly endemic area > 1 yr |
| Hepatitis A | Inactivated | Central or South America, Mexico, Asia( except Japan), Africa, Eastern Europe |
| Meningococcal vaccine | Inactivated | sub-Saharan Africa, Saudi Arabia (during Hajj and Umrah pilgrimage) |
| Japanese encephalitis virus | Inactivated | Rural Japan |
Adapted from Chaudrey et al[55].